Answers are grounded in this paper and cite their sources.
Oral squamous cell carcinoma (OSCC) is an aggressive malignancy driven partly by epigenetic and epitranscriptomic dysregulation. ZNF677 is a candidate tumor suppressor, but its regulation by DNA methylation and N6-methyladenosine (m6A), and its prognostic significance, remain unclear.We integrated clinical, RNA-sequencing and DNA-methylation data from a TCGA-derived OSCC cohort (n = 25). Associations were assessed using Spearman correlation, false-discovery rate control, and bootstrap confidence intervals. Prognostic value was evaluated using Kaplan–Meier and multivariable Cox regression. Mechanistic effects were examined using MeRIP-qPCR, YTHDF2 RIP-qPCR, actinomycin-D decay assays, luciferase reporters, functional assays, and xenograft models. ZNF677 expression inversely correlated with YTHDF2 (ρ=−0.35) and promoter methylation (ρ=−0.36). Although median-dichotomized survival was not significant, continuous ZNF677 independently predicted better survival (HR = 0.10, 95% CI 0.02–0.67; p = 0.017; C-index = 0.85). METTL3 knockdown reduced ZNF677 m6A enrichment and prolonged transcript half-life, whereas METTL3 overexpression shortened it. Restoring ZNF677 suppressed pro-tumorigenic phenotypes (Hedges’ g = − 0.90; p = 0.003) and cancer-stemness markers (g = − 1.59; p = 0.016). ZNF677, METTL3, or YTHDF2 knockdown reduced xenograft tumor volume, whereas METTL3 overexpression increased tumor growth (all Tukey p < 0.001). ZNF677 undergoes coordinated DNA methylation- and METTL3–YTHDF2-dependent repression in OSCC. Higher ZNF677 is associated with improved survival and tumor-suppressive activity, supporting the ZNF677–m6A axis as a potential prognostic and therapeutic target.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: